Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir amibufenamide
- Development stage
- Phase 3
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Tenofovir amibufenamide is an investigational oral prodrug of tenofovir, designed as a nucleotide reverse transcriptase inhibitor (NRTI) for the treatment of chronic hepatitis B virus (HBV) infection. It is structurally and pharmacologically related to tenofovir alafenamide but features a different prodrug moiety intended to improve delivery and reduce systemic exposure. Like other tenofovir prodrugs, it is converted intracellularly to the active metabolite, tenofovir diphosphate, which inhibits HBV polymerase by causing DNA chain termination during viral replication. Tenofovir amibufenamide has been developed primarily in China and has undergone clinical trials for chronic hepatitis B.
- Brand names
- Hengmu
- Other names
- TMBHS-10234HS10234HS 10234
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on tenofovir amibufenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir amibufenamide.